Gastrointestinal Cancer

Richard Kim, MD, discusses selecting between frontline immunotherapy-based regimens in patients with hepatocellular carcinoma.

Amit Mahipal, MD, discusses clinical outcomes with camrelizumab plus rivoceranib in unresectable HCC, based on data from the phase 3 CARES-310 trial.

Davide Melisi, MD, PhD, discusses the potential of NALIRIFOX as a new first-line standard for patients with metastatic pancreatic ductal adenocarcinoma.

The FDA has accepted the filing of an ANDA for Lutetium Lu 177 Dotatate indicated for patients with gastroenteropancreatic neuroendocrine tumors.

Experts in treating cholangiocarcinoma share insights on when biomarker testing is needed and which biomarkers to test for.

Key opinion leaders illustrate how patients with intrahepatic cholangiocarcinoma present in a clinical setting.

The intricate web of risk factors influencing diverse forms of liver cancers are explored.

Haejin In, MD, MPH, MBA, FACS, FSSO, discusses the importance of identifying individuals at high risk for developing gastric cancer.

The FDA has issued a CRL to the zolbetuximab BLA for patients with HER2- gastric or GEJ junction adenocarcinoma whose tumors are Claudin18.2 positive.

China’s NMPA has accepted the sNDA seeking the approval of cadonilimab plus chemotherapy for use in select patients with gastric or GEJ adenocarcinomas.

Significant tumor necrosis greater than 70% occurred in 3 patients with resectable hepatocellular carcinoma following neoadjuvant treatment with low-dose stereotactic body radiation therapy and cemiplimab-rwlc and adjuvant cemiplimab.

Patient care begins with the patient, and Deb Schrag, MD, MPH, has spent her career keeping them the main focus of improving oncologic outcomes.

Richard Kim, MD, discusses a case study of a patient who presented with hepatocellular carcinoma, detailing the steps that were taken upon diagnosis.

The FDA has granted fast track designation to aglatimagene besadenovec plus valacyclovir for use as a potential therapeutic option in patients with pancreatic ductal adenocarcinoma.

The National Medical Products Administration of China has approved sugemalimab paired with fluorouracil and platinum-based chemotherapy for use in the frontline treatment of patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

To close, Dr. Saeed and Dr. Singal share their excitement for the future landscape, emerging agents and treatment strategies for patients with HCC.

Eileen M. O’Reilly, MD, traveled a serendipitous journey from Ireland to the United States, where she has made her mark on transforming gastrointestinal cancer treatment.

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

The European Commission has approved new indications for pembrolizumab in combination with chemotherapy in select patients with gastric or gastroesophageal adenocarcinoma and select patients with biliary tract cancer.

Rui-Hua Xu, MD, PhD, and Kohei Shitara, MD, expand on the advantages of targeting CLDN18.2 with zolbetuximab in gastric/GEJ adenocarcinoma and key efficacy data from the GLOW and SPOTLIGHT trials in support of zolbetuximab’s potential FDA approval.

Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.

Haejin In, MD, MPH, MBA, FACS, FSSO, discusses the increased incidence of gastric cancer in minority patient populations, highlighting the disparities that lead to these patient outcomes in the United States.

Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.

Clinical insights on best practices for treating patients with TROP2-targeted therapy.

The FDA has approved pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.